Abstract
Acute Myeloid Leukemia (AML) is a malignant hematological disorder driven by unregulated proliferation and impaired differentiation of myeloid progenitor cells. The most common treatment for AML is the conventional chemotherapy based on the combination of an anthracycline and cytarabine, leading to several side effects, which may affect the treatment progress. To design new therapeutic ap…